AQR Capital Management LLC Sells 7,725 Shares of 2seventy bio, Inc. (NASDAQ:TSVT)

AQR Capital Management LLC trimmed its stake in 2seventy bio, Inc. (NASDAQ:TSVT) by 4.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 162,182 shares of the company’s stock after selling 7,725 shares during the period. AQR Capital Management LLC’s holdings in 2seventy bio were worth $611,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC purchased a new stake in shares of 2seventy bio in the 2nd quarter valued at $52,000. BBR Partners LLC raised its position in shares of 2seventy bio by 66.7% in the second quarter. BBR Partners LLC now owns 25,000 shares of the company’s stock valued at $96,000 after buying an additional 10,000 shares during the last quarter. Public Employees Retirement System of Ohio raised its position in shares of 2seventy bio by 2,637.0% in the first quarter. Public Employees Retirement System of Ohio now owns 27,370 shares of the company’s stock valued at $146,000 after buying an additional 26,370 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in 2seventy bio by 11.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 28,929 shares of the company’s stock worth $155,000 after purchasing an additional 2,893 shares during the last quarter. Finally, American Century Companies Inc. increased its position in 2seventy bio by 16.6% during the second quarter. American Century Companies Inc. now owns 79,953 shares of the company’s stock worth $308,000 after purchasing an additional 11,363 shares during the last quarter. 93.90% of the stock is owned by hedge funds and other institutional investors.

2seventy bio Stock Up 3.9 %

Shares of NASDAQ:TSVT opened at $5.01 on Monday. 2seventy bio, Inc. has a 52-week low of $1.53 and a 52-week high of $6.40. The company has a market capitalization of $258.02 million, a price-to-earnings ratio of -1.63 and a beta of 1.77. The company has a 50 day moving average of $4.63 and a two-hundred day moving average of $4.53.

2seventy bio (NASDAQ:TSVT) last released its earnings results on Wednesday, August 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.06. The firm had revenue of $8.97 million for the quarter, compared to analyst estimates of $11.43 million. 2seventy bio had a negative return on equity of 66.01% and a negative net margin of 354.16%. On average, equities analysts anticipate that 2seventy bio, Inc. will post -1.23 earnings per share for the current year.

Insider Transactions at 2seventy bio

In other news, insider Jessica Snow sold 7,816 shares of the business’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $4.32, for a total transaction of $33,765.12. Following the sale, the insider now directly owns 156,330 shares in the company, valued at approximately $675,345.60. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 7.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on TSVT shares. Morgan Stanley cut their price objective on shares of 2seventy bio from $7.00 to $6.00 and set an “equal weight” rating for the company in a research report on Monday, July 29th. Wedbush reissued a “neutral” rating and issued a $5.00 price objective on shares of 2seventy bio in a research note on Thursday, June 27th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.00.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.